Trials / Active Not Recruiting
Active Not RecruitingNCT04764227
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and 2-year local control rate for postoperative concurrent chemoradiotherapy for esophageal squamous cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5 |
| DRUG | Carboplatin | carboplatin AUC=2, ivgtt, d1, qw\*5 |
| RADIATION | Radiotherapy | 1.8Gy/d, d1-5/week, 28Fx |
Timeline
- Start date
- 2020-05-30
- Primary completion
- 2024-03-30
- Completion
- 2027-03-30
- First posted
- 2021-02-21
- Last updated
- 2023-08-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04764227. Inclusion in this directory is not an endorsement.